Cargando…
Depressive symptoms in patients diagnosed with benign prostatic hyperplasia
BACKGROUND: Symptoms of depression are common in patients diagnosed with benign prostatic hyperplasia (BPH) and are usually a reaction to deterioration of health, severity of lower urinary tract symptoms, and erectile dysfunction. The aim of this observational study was to evaluate the prevalence of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341023/ https://www.ncbi.nlm.nih.gov/pubmed/25673555 http://dx.doi.org/10.1007/s11255-015-0920-5 |
Sumario: | BACKGROUND: Symptoms of depression are common in patients diagnosed with benign prostatic hyperplasia (BPH) and are usually a reaction to deterioration of health, severity of lower urinary tract symptoms, and erectile dysfunction. The aim of this observational study was to evaluate the prevalence of depressive symptoms in patients diagnosed with BPH and factors affecting their occurrence in a large Polish cohort. PATIENTS AND METHODS: Four thousand thirty-five men (4,035) diagnosed with BPH participated in the survey (age 65 ± 8 years). The occurrence of symptoms of depression was assessed using the Beck depression inventory, severity of lower urinary tract symptoms (LUTS) on the basis of the international prostate symptoms score, and erectile dysfunction using the international index of erectile function (IIEF-5). RESULTS: Depressive symptoms were found in 22.4 % of patients (mild in 20.8 % and moderate/severe in 1.6 %). Erectile dysfunction was found in 71.9 % of patients. Monotherapy for BPH was prescribed to 50.9 % of patients (mostly ARA—selective α1-selective alpha-adrenolytic—47.5 %), while polytherapy (ARA with a 5-alpha reductase inhibitor—5αRI) to 47.9 %. Logistic regression analysis showed a bidirectional relation between the occurrence of depressive symptoms and erectile dysfunction. The occurrence of both depressive symptoms and erectile dysfunction was related to severity of LUTS, nocturia, the use of 5αRI, comorbidity, and sedentary life style. CONCLUSIONS: Prevalence of depressive symptoms in patients diagnosed with BPH is associated with severity of LUTS, erectile dysfunction, nocturia, BPH pharmacotherapy (5αRIs), sedentary life style, and comorbidities including obesity. |
---|